348 related articles for article (PubMed ID: 14734732)
21. Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent.
Ostrand-Rosenberg S; Clements VK; Terabe M; Park JM; Berzofsky JA; Dissanayake SK
J Immunol; 2002 Nov; 169(10):5796-804. PubMed ID: 12421960
[TBL] [Abstract][Full Text] [Related]
22. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
23. Participation of endogenously produced interferon gamma in interleukin 4-mediated tumor rejection.
Nishihori H; Tsuji H; Wang H; Tahara H; Akiyama M; Ogawa Y; Matsushima K; Iwakura Y; Mukaida N
Hum Gene Ther; 2000 Mar; 11(5):659-68. PubMed ID: 10757346
[TBL] [Abstract][Full Text] [Related]
24. IL-4-transfected tumor cell vaccines activate tumor-infiltrating dendritic cells and promote type-1 immunity.
Eguchi J; Kuwashima N; Hatano M; Nishimura F; Dusak JE; Storkus WJ; Okada H
J Immunol; 2005 Jun; 174(11):7194-201. PubMed ID: 15905564
[TBL] [Abstract][Full Text] [Related]
25. Genome-wide analysis of molecular changes in IL-12-induced control of mammary carcinoma via IFN-gamma-independent mechanisms.
Shi X; Cao S; Mitsuhashi M; Xiang Z; Ma X
J Immunol; 2004 Apr; 172(7):4111-22. PubMed ID: 15034023
[TBL] [Abstract][Full Text] [Related]
26. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response.
Cavallo F; Martin-Fontecha A; Bellone M; Heltai S; Gatti E; Tornaghi P; Freschi M; Forni G; Dellabona P; Casorati G
Eur J Immunol; 1995 May; 25(5):1154-62. PubMed ID: 7539748
[TBL] [Abstract][Full Text] [Related]
27. Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor.
Guiducci C; Di Carlo E; Parenza M; Hitt M; Giovarelli M; Musiani P; Colombo MP
J Immunol; 2004 Apr; 172(7):4026-36. PubMed ID: 15034014
[TBL] [Abstract][Full Text] [Related]
28. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
Kemp RA; Ronchese F
J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
[TBL] [Abstract][Full Text] [Related]
29. Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytes.
Giovarelli M; Cappello P; Forni G; Salcedo T; Moore PA; LeFleur DW; Nardelli B; Di Carlo E; Lollini PL; Ruben S; Ullrich S; Garotta G; Musiani P
J Immunol; 2000 Mar; 164(6):3200-6. PubMed ID: 10706711
[TBL] [Abstract][Full Text] [Related]
30. Rat mammary adenocarcinoma 13762 expressing IFN-gamma elicits antitumor CD4+ MHC class II-restricted T cells that are cytolytic in vitro and tumoricidal in vivo.
Frey AB
J Immunol; 1995 May; 154(9):4613-22. PubMed ID: 7722313
[TBL] [Abstract][Full Text] [Related]
31. IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells.
Salcedo R; Stauffer JK; Lincoln E; Back TC; Hixon JA; Hahn C; Shafer-Weaver K; Malyguine A; Kastelein R; Wigginton JM
J Immunol; 2004 Dec; 173(12):7170-82. PubMed ID: 15585838
[TBL] [Abstract][Full Text] [Related]
32. Dendritic cell-tumor coculturing vaccine can induce antitumor immunity through both NK and CTL interaction.
Kim KD; Choi SC; Kim A; Choe YK; Choe IS; Lim JS
Int Immunopharmacol; 2001 Nov; 1(12):2117-29. PubMed ID: 11710541
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
[TBL] [Abstract][Full Text] [Related]
34. Interferon-gamma-producing tumor induces host tumor-specific T cell responses.
Teramura Y; Watanabe Y; Kan N; Masuda T; Kuribayashi K
Jpn J Cancer Res; 1993 Jun; 84(6):689-96. PubMed ID: 8340258
[TBL] [Abstract][Full Text] [Related]
35. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
[TBL] [Abstract][Full Text] [Related]
36. IL-12 administered in vivo to young and aged mice. Discrepancy between the effects on tumor growth in vivo and cytotoxic T lymphocyte generation ex vivo: dependence on IFN-gamma.
Horvath-Arcidiacono JA; Mostowski HS; Bloom ET
Int Immunol; 1996 May; 8(5):661-73. PubMed ID: 8671653
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism.
Rakhmilevich AL; Janssen K; Hao Z; Sondel PM; Yang NS
Cancer Gene Ther; 2000 Jun; 7(6):826-38. PubMed ID: 10880012
[TBL] [Abstract][Full Text] [Related]
38. CD4+ T cells in the absence of the CD8+ cytotoxic T cells are critical and sufficient for NKT cell-dependent tumor rejection.
Hong C; Lee H; Oh M; Kang CY; Hong S; Park SH
J Immunol; 2006 Nov; 177(10):6747-57. PubMed ID: 17082588
[TBL] [Abstract][Full Text] [Related]
39. Chemokine monokine induced by IFN-gamma/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and effector cytokine production.
Whiting D; Hsieh G; Yun JJ; Banerji A; Yao W; Fishbein MC; Belperio J; Strieter RM; Bonavida B; Ardehali A
J Immunol; 2004 Jun; 172(12):7417-24. PubMed ID: 15187119
[TBL] [Abstract][Full Text] [Related]
40. Tumor cells engineered with IL-12 and IL-15 genes induce protective antibody responses in nude mice.
Orengo AM; Di Carlo E; Comes A; Fabbi M; Piazza T; Cilli M; Musiani P; Ferrini S
J Immunol; 2003 Jul; 171(2):569-75. PubMed ID: 12847220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
